EGFR and non-small cell lung carcinoma: To date, this is the first study aimed at investigating the dynamic modification of circulating plasma miRNA levels as a predictor of response to different EGFR-TKIs (gefitinib, erlotinib, and afatinib) in advanced EGFR-mutated NSCLC.